NO20054408D0 - 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose - Google Patents

3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose

Info

Publication number: NO20054408D0
Authority: NO; Norway
Prior art keywords: cyclohexylmethoxyacetic; oxazol; arteriosclerosis; diabetes; methoxy
Prior art date: 2003-02-27

Application number

NO20054408A

Other languages

English (en)

Other versions

NO20054408L (no

Inventor

Heiner Glombik

Eugen Falk

Hans-Ludwig Schaefer

Stefanie Keil

Dirk Gretzke

Christian Stapper

Jochen Goerlitzer

Wolfgang Wendler

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2005-09-22

Publication date

2005-09-22

2005-09-22 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2005-09-22 Publication of NO20054408D0 publication Critical patent/NO20054408D0/no

2005-11-23 Publication of NO20054408L publication Critical patent/NO20054408L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

NO20054408A 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose NO20054408L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001579 WO2004076427A1 (de)	2003-02-27	2004-02-19	3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (2)

Publication Number	Publication Date
NO20054408D0 true NO20054408D0 (no)	2005-09-22
NO20054408L NO20054408L (no)	2005-11-23

Family

ID=32920629

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20054408A NO20054408L (no)	2003-02-27	2005-09-22	3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054396A NO20054396L (no)	2003-02-27	2005-09-22	3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054398A NO20054398L (no)	2003-02-27	2005-09-22	4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20054396A NO20054396L (no)	2003-02-27	2005-09-22	3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054398A NO20054398L (no)	2003-02-27	2005-09-22	4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Country Status (34)

Country	Link
US (5)	US7335671B2 (no)
EP (3)	EP1599453B1 (no)
JP (3)	JP2006519193A (no)
KR (3)	KR20050105492A (no)
CN (3)	CN100398526C (no)
AR (3)	AR043433A1 (no)
AT (3)	ATE365159T1 (no)
AU (3)	AU2004215673B2 (no)
BR (3)	BRPI0407907A (no)
CA (3)	CA2516620A1 (no)
CL (2)	CL2004000392A1 (no)
CO (2)	CO5690580A2 (no)
DE (4)	DE10308355A1 (no)
DK (3)	DK1599453T3 (no)
EC (2)	ECSP055986A (no)
ES (3)	ES2329366T3 (no)
HR (3)	HRP20050742A2 (no)
IL (2)	IL170314A (no)
MA (3)	MA27736A1 (no)
MX (3)	MXPA05008951A (no)
NO (3)	NO20054408L (no)
OA (2)	OA13034A (no)
PA (1)	PA8596801A1 (no)
PE (3)	PE20040959A1 (no)
PL (3)	PL378437A1 (no)
PT (3)	PT1599455E (no)
RS (1)	RS20050594A (no)
RU (3)	RU2005130002A (no)
SA (1)	SA04250153A (no)
TN (2)	TNSN05204A1 (no)
TW (3)	TW200500349A (no)
UY (2)	UY28210A1 (no)
WO (3)	WO2004076428A1 (no)
ZA (2)	ZA200505768B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en)	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) *	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de)	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
RU2008112198A (ru)	2005-09-29	2009-10-10	Санофи-Авентис (Fr)	Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
WO2008018138A1 (en)	2006-08-10	2008-02-14	Wood One Co., Ltd.	Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
CN101801906A (zh)	2007-08-16	2010-08-11	索尔维公司	制备4-氟取代的3-氧代-烷酸酯的方法
CN103360290B (zh) *	2008-02-29	2015-04-01	日产化学工业株式会社	噻吩化合物及其中间体的制造方法
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
EP4050422B1 (en)	2017-12-13	2024-11-20	Canon Kabushiki Kaisha	Cartridge and image forming apparatus
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en)	1993-02-15	1995-08-14	Wellcome Found	Hypolipidaemic compounds
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
KR100556067B1 (ko)	1996-08-30	2006-03-07	노보 노르디스크 에이/에스	지엘피 - 1 유도체
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
IL127296A (en)	1996-12-31	2003-01-12	Reddy Research Foundation	Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru)	1997-07-16	2003-10-27	Ново Нордиск А/С	Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) *	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) *	1998-08-27	2006-08-17	오노 야꾸힝 고교 가부시키가이샤	카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1173438A1 (en)	1999-04-16	2002-01-23	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
CZ20013834A3 (cs) *	1999-04-28	2002-04-17	Aventis Pharma Deutschland Gmbh	Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
CA2371271A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
DE60029446T2 (de)	1999-06-18	2007-02-08	Merck & Co., Inc.	Arylthiazolidindione und aryloxazolidindion-derivate
JP2003504082A (ja)	1999-07-09	2003-02-04	コヘージョンテクノロジーズ，インコーポレイテッド	エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
US6967201B1 (en)	1999-07-29	2005-11-22	Eli Lilly And Company	Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
CA2383781A1 (en) *	1999-09-01	2001-03-08	Aventis Pharma Deutschland Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI260321B (en)	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
MXPA02005327A (es)	1999-12-03	2002-12-06	Astrazeneca Ab	Forma cristalina del acido (s)-2- etoxi- 3-(4-(2-(4- metanosulfoniloxifenil) etoxi) fenil) propanoico.
ES2525041T3 (es)	2000-03-31	2014-12-16	Royalty Pharma Collection Trust	Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
IL152224A0 (en)	2000-04-25	2003-05-29	Kyorin Seiyaku Kk	Stable crystals of thiazolidinedione derivative and process for the preparation thereof
WO2001083451A1 (en)	2000-04-28	2001-11-08	Asahi Kasei Kabushiki Kaisha	Novel bicyclic compounds
WO2001085695A1 (en)	2000-05-11	2001-11-15	Bristol-Myers Squibb Co.	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001091752A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
YU91002A (sh) *	2000-06-09	2006-05-25	Aventis Pharma Deutschland	Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
AU2001284658A1 (en)	2000-08-23	2002-03-13	Eli Lilly And Company	Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
DK1313716T3 (da) *	2000-08-23	2007-08-27	Lilly Co Eli	Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja)	2000-12-05	2004-04-08	杏林製薬株式会社	置換カルボン酸誘導体
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
DE50111751D1 (de)	2000-12-21	2007-02-08	Sanofi Aventis Deutschland	Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
CZ20031772A3 (cs) *	2000-12-25	2003-11-12	Ono Pharmaceutical Co., Ltd.	Derivát dihydronaftalenu a činidlo obsahující tento derivát jako účinnou složku
WO2002064549A1 (en) *	2001-02-15	2002-08-22	Pfizer Products Inc.	Ppar agonists
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CN1578659A (zh) *	2001-06-07	2005-02-09	伊莱利利公司	过氧化物酶体增殖剂激活的受体(ppar)的调节剂
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
DE50208960D1 (de)	2001-08-31	2007-01-25	Sanofi Aventis Deutschland	Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
AU2003207432A1 (en)	2002-02-05	2003-09-02	Eli Lilly And Company	Urea linker derivatives for use as ppar modulators
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en)	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Ceased
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Ceased
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Ceased
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de not_active Ceased
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de not_active Ceased
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de not_active Ceased
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en not_active Expired - Lifetime
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2004215673A1 (en)	2004-09-10
CL2004000391A1 (es)	2005-01-07
DE502004009690D1 (de)	2009-08-13
PL378437A1 (pl)	2006-04-03
MXPA05008951A (es)	2005-11-04
ES2287700T3 (es)	2007-12-16
BRPI0407907A (pt)	2006-02-14
ECSP055986A (es)	2006-01-16
CA2517386A1 (en)	2004-09-10
TNSN05204A1 (en)	2007-06-11
CL2004000392A1 (es)	2005-04-22
CN100398526C (zh)	2008-07-02
MXPA05008988A (es)	2005-10-18
AU2004215672A1 (en)	2004-09-10
CN100439345C (zh)	2008-12-03
AU2004215672B2 (en)	2010-01-07
AR043432A1 (es)	2005-07-27
EP1599453B1 (de)	2009-05-06
ZA200505768B (en)	2005-11-23
TW200500349A (en)	2005-01-01
PT1599455E (pt)	2009-09-29
US20080167354A1 (en)	2008-07-10
EP1599453A1 (de)	2005-11-30
DK1599455T3 (da)	2009-11-09
TW200508210A (en)	2005-03-01
TNSN05206A1 (en)	2007-06-11
JP2006519199A (ja)	2006-08-24
CO5690578A2 (es)	2006-10-31
DE10308355A1 (de)	2004-12-23
US20080015238A1 (en)	2008-01-17
CO5690580A2 (es)	2006-10-31
US20040209920A1 (en)	2004-10-21
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
ZA200505765B (en)	2006-05-31
DK1599453T3 (da)	2009-08-24
JP2006519194A (ja)	2006-08-24
DK1599452T3 (da)	2007-10-01
WO2004076428A1 (de)	2004-09-10
RU2005129995A (ru)	2006-01-27
WO2004076426A1 (de)	2004-09-10
AR043433A1 (es)	2005-07-27
MA27742A1 (fr)	2006-02-01
MXPA05008995A (es)	2005-10-18
UY28209A1 (es)	2004-09-30
AU2004215677A1 (en)	2004-09-10
PL377735A1 (pl)	2006-02-20
EP1599452B1 (de)	2007-06-20
DE502004009453D1 (de)	2009-06-18
ES2326418T3 (es)	2009-10-09
NO20054398D0 (no)	2005-09-22
PE20040959A1 (es)	2005-01-17
WO2004076427A1 (de)	2004-09-10
CN1753881A (zh)	2006-03-29
US7365084B2 (en)	2008-04-29
CN1756748A (zh)	2006-04-05
US20050101637A1 (en)	2005-05-12
TW200510352A (en)	2005-03-16
MA27736A1 (fr)	2006-02-01
KR20050106462A (ko)	2005-11-09
PE20050293A1 (es)	2005-05-24
US7872034B2 (en)	2011-01-18
PT1599452E (pt)	2007-09-12
AU2004215677B2 (en)	2010-01-07
CA2516620A1 (en)	2004-09-10
ATE365159T1 (de)	2007-07-15
CA2517381A1 (en)	2004-09-10
OA13035A (en)	2006-11-10
BRPI0407814A (pt)	2006-02-14
ATE430738T1 (de)	2009-05-15
UY28210A1 (es)	2004-09-30
SA04250153A (ar)	2005-12-03
PT1599453E (pt)	2009-07-14
ECSP055985A (es)	2006-01-16
BRPI0407758A (pt)	2006-02-14
ES2329366T3 (es)	2009-11-25
AU2004215673B2 (en)	2009-10-01
NO20054396L (no)	2005-11-11
RS20050594A (sr)	2007-12-31
PE20050292A1 (es)	2005-05-24
EP1599455B1 (de)	2009-07-01
MA27737A1 (fr)	2006-02-01
KR20050106461A (ko)	2005-11-09
ATE435217T1 (de)	2009-07-15
AR043427A1 (es)	2005-07-27
KR20050105492A (ko)	2005-11-04
NO20054396D0 (no)	2005-09-22
EP1599452A1 (de)	2005-11-30
US20050215596A1 (en)	2005-09-29
IL170314A (en)	2010-11-30
RU2005130002A (ru)	2006-01-27
PL378130A1 (pl)	2006-03-06
CN1753879A (zh)	2006-03-29
RU2005129992A (ru)	2006-02-10
NO20054398L (no)	2005-11-02
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
CN100439347C (zh)	2008-12-03
EP1599455A1 (de)	2005-11-30
HRP20050742A2 (en)	2006-09-30
JP2006519193A (ja)	2006-08-24
US7335671B2 (en)	2008-02-26
DE502004004139D1 (de)	2007-08-02
US7259177B2 (en)	2007-08-21
OA13034A (en)	2006-11-10
HRP20050744A2 (en)	2006-09-30

Publication	Publication Date	Title
NO20054408D0 (no)	2005-09-22	3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20020764L (no)	2002-04-17	Benzosyrederivater for behandling av diabetes mellitus
DK1644357T3 (da)	2008-04-21	Trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af lidelser relateret dertil
NO20053041D0 (no)	2005-06-21	Behandling av diabetes.
NO20035086L (no)	2003-11-14	Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
NO20035496D0 (no)	2003-12-10	Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes
ATE410430T1 (de)	2008-10-15	2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20022087D0 (no)	2002-05-02	Fremgangsmåte for behandling av diabetes
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
AU2003279442A1 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PL377164A1 (pl)	2006-01-23	Pochodne anilinopirazolu przydatne do leczenia cukrzycy
NO20043842L (no)	2004-09-14	Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
NO20063576L (no)	2006-10-06	1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
DK1539746T3 (da)	2007-03-26	N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
DK1551814T3 (da)	2008-10-27	Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister
DE60318327D1 (de)	2008-02-07	Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
NO20043483L (no)	2004-08-20	Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
DE60331359D1 (de)	2010-04-01	Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE60311822D1 (de)	2007-03-29	Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
DE602006002608D1 (de)	2008-10-16	4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
NO20035642D0 (no)	2003-12-17	Fremgangsmåte for fremstilling av derivater av 1,5-diaryl-3- trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene
NO20025883D0 (no)	2002-12-06	Tiazolidinonsalt for behandling av diabetes mellitus